The FDA has approved tucatinib (TUKYSA) in combination with trastuzumab and pertuzumab as first-line maintenance treatment for adults with HER2-positive metastatic breast cancer based on the Phase 3 HER2CLIMB-05 trial. Erika Hamilton, MD, presented the trial results at #SABCS25.
October 7, 2026 at 10:48 PM
The FDA has approved tucatinib (TUKYSA) in combination with trastuzumab and pertuzumab as first-line maintenance treatment for adults with HER2-positive metastatic breast cancer based on the Phase 3 HER2CLIMB-05 trial. Erika Hamilton, MD, presented the trial results at #SABCS25.
Camizestrant received accelerated FDA approval Friday. At #SABCS25, François-Clément Bidard, MD, presented updated Phase 3 SERENA-6 results showing how ctDNA can detect treatment resistance before disease progression. What will we see next? Join us at #SABCS26, Dec. 8–11. https://bit.ly/463weSl
September 5, 2026 at 8:55 PM
Camizestrant received accelerated FDA approval Friday. At #SABCS25, François-Clément Bidard, MD, presented updated Phase 3 SERENA-6 results showing how ctDNA can detect treatment resistance before disease progression. What will we see next? Join us at #SABCS26, Dec. 8–11. https://bit.ly/463weSl
New data presented at #SABCS25 shows that adding a breast MRI to a diagnostic mammogram does not improve five-year recurrence rates for patients with stage I/II HR negative breast cancer. spr.ly/63320C8iqk #OncSky #EndCancer
December 11, 2025 at 3:46 PM
New data presented at #SABCS25 shows that adding a breast MRI to a diagnostic mammogram does not improve five-year recurrence rates for patients with stage I/II HR negative breast cancer. spr.ly/63320C8iqk #OncSky #EndCancer
NOW OUT!! The #SABCS25 COMPLETE Newsletter
REGISTER TO GET IT at 👉 oncoalert.m-pages.com/nhMpwe/oncoale
rt-newsletter-registration
OUR PICKS of The TOP Trials from SAN ANTONIO ALL IN ONE PLACE!!
#BreastCancer
REGISTER TO GET IT at 👉 oncoalert.m-pages.com/nhMpwe/oncoale
rt-newsletter-registration
OUR PICKS of The TOP Trials from SAN ANTONIO ALL IN ONE PLACE!!
#BreastCancer
December 15, 2025 at 12:44 PM
NOW OUT!! The #SABCS25 COMPLETE Newsletter
REGISTER TO GET IT at 👉 oncoalert.m-pages.com/nhMpwe/oncoale
rt-newsletter-registration
OUR PICKS of The TOP Trials from SAN ANTONIO ALL IN ONE PLACE!!
#BreastCancer
REGISTER TO GET IT at 👉 oncoalert.m-pages.com/nhMpwe/oncoale
rt-newsletter-registration
OUR PICKS of The TOP Trials from SAN ANTONIO ALL IN ONE PLACE!!
#BreastCancer
Colleagues following #SABCS25 , Our Collaborators at @high5md have you covered with TOP international #BreastCancer Experts reporting LIVE from San Antonio 👉 buff.ly/HrPcYSq
Join them & their experts now and get KEY insights into the TOP trials presented at the Alamo City
Join them & their experts now and get KEY insights into the TOP trials presented at the Alamo City
December 13, 2025 at 3:01 PM
Colleagues following #SABCS25 , Our Collaborators at @high5md have you covered with TOP international #BreastCancer Experts reporting LIVE from San Antonio 👉 buff.ly/HrPcYSq
Join them & their experts now and get KEY insights into the TOP trials presented at the Alamo City
Join them & their experts now and get KEY insights into the TOP trials presented at the Alamo City
Colleagues following #SABCS25 , Our Collaborators at High5Md have you covered with TOP international #BreastCancer Experts reporting LIVE from San Antonio 👉 high5oncology.tv/meeting-cove....
Join them now and get KEY insights into the TOP trials presented at the Alamo City
Join them now and get KEY insights into the TOP trials presented at the Alamo City
December 12, 2025 at 10:09 PM
Colleagues following #SABCS25 , Our Collaborators at High5Md have you covered with TOP international #BreastCancer Experts reporting LIVE from San Antonio 👉 high5oncology.tv/meeting-cove....
Join them now and get KEY insights into the TOP trials presented at the Alamo City
Join them now and get KEY insights into the TOP trials presented at the Alamo City
Colleagues following #SABCS25 , Our Collaborators at High5Md have you covered with TOP international #BreastCancer Experts reporting LIVE from San Antonio 👉 high5oncology.tv/meeting-cove...
Join them now and get KEY insights into the TOP trials presented at the Alamo City
Join them now and get KEY insights into the TOP trials presented at the Alamo City
December 12, 2025 at 5:00 PM
Colleagues following #SABCS25 , Our Collaborators at High5Md have you covered with TOP international #BreastCancer Experts reporting LIVE from San Antonio 👉 high5oncology.tv/meeting-cove...
Join them now and get KEY insights into the TOP trials presented at the Alamo City
Join them now and get KEY insights into the TOP trials presented at the Alamo City
Dear Colleagues at #SABCS25
Our Collaborators at @high5md are on site in San Antonio, bringing you exclusive insights, expert voices, and the latest highlights straight from the congress floor.
Their Channel GOES LIVE TOMORROW:
Dec 12 at 12:00 PM CET
high5oncology.tv/meeting-cove...
Our Collaborators at @high5md are on site in San Antonio, bringing you exclusive insights, expert voices, and the latest highlights straight from the congress floor.
Their Channel GOES LIVE TOMORROW:
Dec 12 at 12:00 PM CET
high5oncology.tv/meeting-cove...
December 11, 2025 at 7:37 PM
Dear Colleagues at #SABCS25
Our Collaborators at @high5md are on site in San Antonio, bringing you exclusive insights, expert voices, and the latest highlights straight from the congress floor.
Their Channel GOES LIVE TOMORROW:
Dec 12 at 12:00 PM CET
high5oncology.tv/meeting-cove...
Our Collaborators at @high5md are on site in San Antonio, bringing you exclusive insights, expert voices, and the latest highlights straight from the congress floor.
Their Channel GOES LIVE TOMORROW:
Dec 12 at 12:00 PM CET
high5oncology.tv/meeting-cove...
A Great Evening with our friends at MEDSIR here in #SABCS25 for MEDiscussion
Amazing Global experts discussing the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org
Our thanks to:
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
Thank you for joining us!!
Amazing Global experts discussing the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org
Our thanks to:
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
Thank you for joining us!!
December 11, 2025 at 7:15 PM
A Great Evening with our friends at MEDSIR here in #SABCS25 for MEDiscussion
Amazing Global experts discussing the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org
Our thanks to:
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
Thank you for joining us!!
Amazing Global experts discussing the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org
Our thanks to:
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
Thank you for joining us!!
Dear Colleagues at #SABCS25
Our Collaborators at @high5md are on site in San Antonio, bringing you exclusive insights, expert voices, and the latest highlights straight from the congress floor.
Their Channel GOES LIVE TOMORROW:
Dec 12 at 12:00 PM CET
high5oncology.tv/meeting-cove...
Our Collaborators at @high5md are on site in San Antonio, bringing you exclusive insights, expert voices, and the latest highlights straight from the congress floor.
Their Channel GOES LIVE TOMORROW:
Dec 12 at 12:00 PM CET
high5oncology.tv/meeting-cove...
December 11, 2025 at 3:05 PM
Dear Colleagues at #SABCS25
Our Collaborators at @high5md are on site in San Antonio, bringing you exclusive insights, expert voices, and the latest highlights straight from the congress floor.
Their Channel GOES LIVE TOMORROW:
Dec 12 at 12:00 PM CET
high5oncology.tv/meeting-cove...
Our Collaborators at @high5md are on site in San Antonio, bringing you exclusive insights, expert voices, and the latest highlights straight from the congress floor.
Their Channel GOES LIVE TOMORROW:
Dec 12 at 12:00 PM CET
high5oncology.tv/meeting-cove...
DEAR COLLEAGUES IN SAN ANTONIO
A Special invitation to JOIN US LIVE at MEDiscussion during #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org/events/medtalk
TOMORROW DEC 10, 2025 FREE REGISTRATION
A Special invitation to JOIN US LIVE at MEDiscussion during #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org/events/medtalk
TOMORROW DEC 10, 2025 FREE REGISTRATION
December 10, 2025 at 10:37 AM
DEAR COLLEAGUES IN SAN ANTONIO
A Special invitation to JOIN US LIVE at MEDiscussion during #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org/events/medtalk
TOMORROW DEC 10, 2025 FREE REGISTRATION
A Special invitation to JOIN US LIVE at MEDiscussion during #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org/events/medtalk
TOMORROW DEC 10, 2025 FREE REGISTRATION
MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org/events/medtalk
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
December 8, 2025 at 1:43 PM
MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org/events/medtalk
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
Dear Colleagues,
#SABCS25 is finally upon us, and OncoAlert is honored—as always—to collaborate with our esteemed partners at SABCS and welcome you to our home, the Alamo City in the great state of Texas.
#SABCS25 is finally upon us, and OncoAlert is honored—as always—to collaborate with our esteemed partners at SABCS and welcome you to our home, the Alamo City in the great state of Texas.
December 8, 2025 at 12:55 PM
Dear Colleagues,
#SABCS25 is finally upon us, and OncoAlert is honored—as always—to collaborate with our esteemed partners at SABCS and welcome you to our home, the Alamo City in the great state of Texas.
#SABCS25 is finally upon us, and OncoAlert is honored—as always—to collaborate with our esteemed partners at SABCS and welcome you to our home, the Alamo City in the great state of Texas.
An Honor for OncoAlert 🚨 To announce that our Special Collaboration with SABCS continues for the 3rd Year Running! Welcome to the Alamo City for what is always OUR Home Coming for The OncoAlert Network, the San Antonio Breast Cancer Symposium #SABCS25 #BreastCancer
See Y'all Real Soon
The Network
See Y'all Real Soon
The Network
December 4, 2025 at 2:06 PM
An Honor for OncoAlert 🚨 To announce that our Special Collaboration with SABCS continues for the 3rd Year Running! Welcome to the Alamo City for what is always OUR Home Coming for The OncoAlert Network, the San Antonio Breast Cancer Symposium #SABCS25 #BreastCancer
See Y'all Real Soon
The Network
See Y'all Real Soon
The Network
MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org/events/medtalk
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
December 3, 2025 at 1:23 PM
MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org/events/medtalk
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
MEDSIR invites you to their MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease & ctDNA. 👉 buff.ly/qC8Poj0
FREE REGISTRATION
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
FREE REGISTRATION
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
November 28, 2025 at 5:45 PM
MEDSIR invites you to their MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease & ctDNA. 👉 buff.ly/qC8Poj0
FREE REGISTRATION
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
FREE REGISTRATION
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org/events/medtalk
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
November 24, 2025 at 7:17 PM
MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org/events/medtalk
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
Adjuvant abemaciclib improved overall survival in high-risk HR+/HER2- early breast cancer in monarchE—remarkable for the adjuvant setting. At #SABCS25, updated analyses by nodal status (N1–N3) further clarified outcomes.
Read the expert highlights: https://bit.ly/4u7Hjwq
#BreastCancer #Oncology
Read the expert highlights: https://bit.ly/4u7Hjwq
#BreastCancer #Oncology
March 19, 2026 at 10:22 PM
Adjuvant abemaciclib improved overall survival in high-risk HR+/HER2- early breast cancer in monarchE—remarkable for the adjuvant setting. At #SABCS25, updated analyses by nodal status (N1–N3) further clarified outcomes.
Read the expert highlights: https://bit.ly/4u7Hjwq
#BreastCancer #Oncology
Read the expert highlights: https://bit.ly/4u7Hjwq
#BreastCancer #Oncology
With co-director @vkaklamani.bsky.social of @sabcs.bsky.social we have been working on #SABCS25 program! Stay tuned! Super exciting with stellar line-up of speakers. With @heidefordlab.bsky.social @itsnotpink.bsky.social and many other fantastic faculty members #bcsm
March 1, 2025 at 4:04 PM
With co-director @vkaklamani.bsky.social of @sabcs.bsky.social we have been working on #SABCS25 program! Stay tuned! Super exciting with stellar line-up of speakers. With @heidefordlab.bsky.social @itsnotpink.bsky.social and many other fantastic faculty members #bcsm
What a week at #SABCS25! Grateful to share results from initiatives, developed in partnership with Living Beyond Breast Cancer, Surviving Breast Cancer, & Salud America. We spotlighted toxicity management, #HER2-aligned decisions & equity in #TNBC for Hispanic/Latina communities. 🔗 bit.ly/3KNajrO
December 15, 2025 at 8:59 PM
What a week at #SABCS25! Grateful to share results from initiatives, developed in partnership with Living Beyond Breast Cancer, Surviving Breast Cancer, & Salud America. We spotlighted toxicity management, #HER2-aligned decisions & equity in #TNBC for Hispanic/Latina communities. 🔗 bit.ly/3KNajrO
📣 We'll be at #SABCS25 presenting topics in #BreastCancer care:
Managing complex toxicities 👉 12/10 from 12:30–2:30 PM
Advancing equity for #TNBC 👉 12/10 from 5–6:30 PM
HER2 expression 👉 12/12 from 12:30–2 PM
🔗 bit.ly/3XNtrJ0
👥 Surviving Breast Cancer, Salud America, Living Beyond Breast Cancer
Managing complex toxicities 👉 12/10 from 12:30–2:30 PM
Advancing equity for #TNBC 👉 12/10 from 5–6:30 PM
HER2 expression 👉 12/12 from 12:30–2 PM
🔗 bit.ly/3XNtrJ0
👥 Surviving Breast Cancer, Salud America, Living Beyond Breast Cancer
December 9, 2025 at 7:58 PM
📣 We'll be at #SABCS25 presenting topics in #BreastCancer care:
Managing complex toxicities 👉 12/10 from 12:30–2:30 PM
Advancing equity for #TNBC 👉 12/10 from 5–6:30 PM
HER2 expression 👉 12/12 from 12:30–2 PM
🔗 bit.ly/3XNtrJ0
👥 Surviving Breast Cancer, Salud America, Living Beyond Breast Cancer
Managing complex toxicities 👉 12/10 from 12:30–2:30 PM
Advancing equity for #TNBC 👉 12/10 from 5–6:30 PM
HER2 expression 👉 12/12 from 12:30–2 PM
🔗 bit.ly/3XNtrJ0
👥 Surviving Breast Cancer, Salud America, Living Beyond Breast Cancer
Proud to stand alongside incredible partners at #SABCS25 this year, like Living Beyond Breast Cancer, Surviving Breast Cancer, & Salud America. 💗 We'll be onsite highlighting outcomes from our latest educational initiatives in #BreastCancer. Attending? Stop by! 🔗 bit.ly/4iy58Ix
@sabcs.bsky.social
@sabcs.bsky.social
December 2, 2025 at 10:26 PM
Proud to stand alongside incredible partners at #SABCS25 this year, like Living Beyond Breast Cancer, Surviving Breast Cancer, & Salud America. 💗 We'll be onsite highlighting outcomes from our latest educational initiatives in #BreastCancer. Attending? Stop by! 🔗 bit.ly/4iy58Ix
@sabcs.bsky.social
@sabcs.bsky.social
Results from the RADIOLA study by #SOLTI and #VHIO, led by Isabel Pimentel, Judith Balmaña and Aleix Prat: the RAD51 test identifies metastatic gBRCA, HER2− #BreastCancer patients who are 7 times more likely to respond to olaparib.
➡️ https://linke.to/RADIOLAVHIO
#SABCS25 @hospitalclinic.bsky.social
➡️ https://linke.to/RADIOLAVHIO
#SABCS25 @hospitalclinic.bsky.social
December 14, 2025 at 12:01 PM
Results from the RADIOLA study by #SOLTI and #VHIO, led by Isabel Pimentel, Judith Balmaña and Aleix Prat: the RAD51 test identifies metastatic gBRCA, HER2− #BreastCancer patients who are 7 times more likely to respond to olaparib.
➡️ https://linke.to/RADIOLAVHIO
#SABCS25 @hospitalclinic.bsky.social
➡️ https://linke.to/RADIOLAVHIO
#SABCS25 @hospitalclinic.bsky.social
L’estudi RADIOLA (#SOLTI–#VHIO), amb Isabel Pimentel, Judith Balmaña i Aleix Prat, mostra que el test RAD51 identifica quines pacients amb #CàncerDeMama metastàtic gBRCA, HER2− podrien respondre fins a 7 vegades més a l’olaparib
➡️ https://linke.to/RADIOLAVHIO_Cat
@hospitalclinic.bsky.social #SABCS25
➡️ https://linke.to/RADIOLAVHIO_Cat
@hospitalclinic.bsky.social #SABCS25
December 12, 2025 at 7:51 PM
L’estudi RADIOLA (#SOLTI–#VHIO), amb Isabel Pimentel, Judith Balmaña i Aleix Prat, mostra que el test RAD51 identifica quines pacients amb #CàncerDeMama metastàtic gBRCA, HER2− podrien respondre fins a 7 vegades més a l’olaparib
➡️ https://linke.to/RADIOLAVHIO_Cat
@hospitalclinic.bsky.social #SABCS25
➡️ https://linke.to/RADIOLAVHIO_Cat
@hospitalclinic.bsky.social #SABCS25
Presentado en #SABCS25 el estudio RADIOLA, de #SOLTI y #VHIO, con Isabel Pimentel, Judith Balmaña y Aleix Prat: el test RAD51 identifica pacientes de #CáncerDeMama metastásico gBRCA, HER2- con hasta 7 veces más respuesta a olaparib.
➡️ https://linke.to/RADIOLAVHIO_Cast
@hospitalclinic.bsky.social
➡️ https://linke.to/RADIOLAVHIO_Cast
@hospitalclinic.bsky.social
December 12, 2025 at 7:41 PM
Presentado en #SABCS25 el estudio RADIOLA, de #SOLTI y #VHIO, con Isabel Pimentel, Judith Balmaña y Aleix Prat: el test RAD51 identifica pacientes de #CáncerDeMama metastásico gBRCA, HER2- con hasta 7 veces más respuesta a olaparib.
➡️ https://linke.to/RADIOLAVHIO_Cast
@hospitalclinic.bsky.social
➡️ https://linke.to/RADIOLAVHIO_Cast
@hospitalclinic.bsky.social